+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antimicrobial Therapeutics Market by Application and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Antimicrobial Therapeutics Market by Application and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4792957
  • Report
  • June 2019
  • Region: Global
  • 135 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co Inc.
  • Pfizer Inc.
  • Sanofi
  • MORE
Global Antimicrobial Therapeutics Market: About this market

Antimicrobial drugs include antibiotics, antifungals, antiprotozoal, and antivirals, which help kill microorganisms or inhibit their growth. This antimicrobial therapeutics market analysis considers sales from applications including antiviral, antibacterial, antifungal, and antiparasitic. Our analysis also considers the sales of antimicrobial therapeutics in Asia, Europe, North America, and ROW. In 2018, the antiviral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising incidence of viral infections, including HIV, hepatitis, and influenza, will play a significant role in the antiviral segment to maintain its market position. Also, our global antimicrobial therapeutics market report looks at factors such as recent drug approvals and robust pipeline, initiatives from government agencies, and rising awareness about microbial diseases. However, the increasing availability of generic drugs, challenges associated with development, storage, and handling of vaccines, and rising antimicrobial resistance may hamper the growth of the antimicrobial therapeutics industry over the forecast period.

Global Antimicrobial Therapeutics market: Overview

Recent drug approvals and robust pipeline

Researchers are investing in R&D on new drugs and vaccines due to the growing prevalence of microbial diseases. This has created a strong drug pipeline involving innovative disease-modifying agents. Researchers are also focusing on the development of several advanced novel therapeutic solutions. The approval of these vaccines and therapeutic solutions will lead to the expansion of the global antimicrobial therapeutics market at a CAGR of almost 4% during the forecast period.

Increase in disease diagnostic modalities

There is an increase in the demand for high-quality diagnostics that will enable early diagnosis of the infection. This is encouraging various companies to develop sophisticated diagnostic modalities, biomarkers, and PoC diagnostic tests. The development of such innovative diagnostics is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global antimicrobial therapeutics market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antimicrobial therapeutics manufacturers, that include Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., and Sanofi.

Also, the antimicrobial therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co Inc.
  • Pfizer Inc.
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Antiviral - Market size and forecast 2018-2023
  • Antibacterial - Market size and forecast 2018-2023
  • Antifungal - Market size and forecast 2018-2023
  • Antiparasitic - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increase in R&D of therapeutic vaccines
  • Increased disease diagnostic modalities
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co Inc.
  • Pfizer Inc.
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Application - Market share 2018-2023 (%)
Exhibit 18: Comparison by application
Exhibit 19: Antiviral - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antiviral - Year-over-year growth 2019-2023 (%)
Exhibit 21: Antibacterial - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antibacterial - Year-over-year growth 2019-2023 (%)
Exhibit 23: Antifungal - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antifungal - Year-over-year growth 2019-2023 (%)
Exhibit 25: Antiparasitic - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antiparasitic - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by application
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Some of the late-stage molecules
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Therapeutic vaccines
Exhibit 44: Some of the recent POC diagnostics approvals in the US
Exhibit 45: Some of the recently approved combination therapy drugs
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Gilead Sciences, Inc. - Vendor overview
Exhibit 52: Gilead Sciences, Inc. - Business segments
Exhibit 53: Gilead Sciences, Inc. - Organizational developments
Exhibit 54: Gilead Sciences, Inc. - Geographic focus
Exhibit 55: Gilead Sciences, Inc. - Segment focus
Exhibit 56: Gilead Sciences, Inc. - Key offerings
Exhibit 57: GlaxoSmithKline plc - Vendor overview
Exhibit 58: GlaxoSmithKline plc - Business segments
Exhibit 59: GlaxoSmithKline plc - Organizational developments
Exhibit 60: GlaxoSmithKline plc - Geographic focus
Exhibit 61: GlaxoSmithKline plc - Segment focus
Exhibit 62: GlaxoSmithKline plc - Key offerings
Exhibit 63: GlaxoSmithKline plc - Key offerings
Exhibit 64: Merck & Co Inc. - Vendor overview
Exhibit 65: Merck & Co Inc. - Business segments
Exhibit 66: Merck & Co Inc. - Organizational developments
Exhibit 67: Merck & Co Inc. - Geographic focus
Exhibit 68: Merck & Co Inc. - Segment focus
Exhibit 69: Merck & Co Inc. - Key offerings
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Sanofi - Vendor overview
Exhibit 77: Sanofi - Business segments
Exhibit 78: Sanofi - Organizational developments
Exhibit 79: Sanofi - Geographic focus
Exhibit 80: Sanofi - Segment focus
Exhibit 81: Sanofi - Key offerings
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co Inc.
  • Pfizer Inc.
  • Sanofi
  • MORE
The following companies are recognised as the key players in the global antimicrobial therapeutics market: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in disease diagnostic modalities.”

According to the report, one of the major drivers for this market is the recent drug approvals and robust pipeline.

Further, the report states that one of the major factors hindering the growth of this market is the rising antimicrobial resistance.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co Inc.
  • Pfizer Inc.
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll